HomeAI · summaries
Storia in 3 fonti
Manufacturing problems cited in FDA rejection of ITM's radiopharma drug
The FDA rejected ITM's radiopharmaceutical for neuroendocrine tumors because of manufacturing issues, delaying a potential challenger to Novartis’ Lutathera.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
The FDA has rejected a radiopharmaceutical therapy due to manufacturing issues, halting what would have been a competitor for Novartis.
- ·
fiercepharma.com
ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualms
The FDA has denied ITM Isotopes Techn | The FDA has denied ITM Isotopes Technologies’ lead pipeline candidate for a rare group of tumors due to qualms over the drug’s…
